Tris-Edta

Verify with FDA CVM →

82 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
82
Total Reports
7
Deaths Reported
850.0%
Death Rate

Active Ingredients

Tris-Edta

Administration Routes

Auricular (Otic)UnknownOtherTopicalOral

Species Affected

Dog 73
Cat 9

Most Affected Breeds

Retriever - Golden 9
Retriever - Labrador 8
Shih Tzu 7
Domestic Shorthair 7
Pit Bull 5
Shepherd Dog - German 4
Bulldog 2
Maltese 2
Poodle (unspecified) 2
Schnauzer - Miniature 2

Most Reported Reactions

Lack of efficacy - NOS 24
Not eating 10
Head tilt - ear disorder 10
Ear discharge 9
Decreased appetite 9
Vomiting 8
Nystagmus 8
Behavioural disorder NOS 7
Loss of hearing 7
Death by euthanasia 7
Lethargy (see also Central nervous system depression in Neurological) 7
Head shake - ear disorder 6

Outcome Breakdown

Outcome Unknown
35 (42.7%)
Ongoing
29 (35.4%)
Euthanized
7 (8.5%)
Recovered/Normal
6 (7.3%)
Recovered with Sequela
5 (6.1%)

Data Summary

Metric Value
Total adverse event reports 82
Reports involving death 7
Case-fatality rate (reported events) 850.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Tris-Edta Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 82 adverse event reports referencing Tris-Edta, including 7 reports in which the animal died — a 850.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Tris-Edta. Reported administration routes include Auricular (Otic), Unknown, Other, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Tris-Edta reports are Dog (73 reports), Cat (9 reports), with Dog accounting for the largest share. Within those species, Retriever - Golden (9), Retriever - Labrador (8), Shih Tzu (7) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Tris-Edta are Lack of efficacy - NOS (24), Not eating (10), Head tilt - ear disorder (10), Ear discharge (9). Of the 82 reports with a coded outcome, Outcome Unknown is the leading category at 42.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Tris-Edta.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial